Warrington-based Windtree Therapeutics Finds Its New Executive Director of Clinical Development


Warrington-based Windtree Therapeutics, a biotechnology and medical device company, has appointed Joseph Soffer, M.D., F.A.C.C., as its new Executive Director of Clinical Development, effective immediately.

“We are thrilled to welcome Joe to lead our cardiovascular clinical development efforts at such an important time for Windtree,” said Dr. Steve Simonson, Chief Medical Officer at Windtree Therapeutics.

He added that Soffer’s expertise in cardiology along with his “substantial experience with drug development in the pharmaceutical industry will be invaluable to our istaroxime program in acute heart failure, including our study in early cardiogenic shock.”

Soffer is a Board-certified physician in Cardiology and Internal Medicine with more than three decades of combined experience in the industry, clinical practice, and academia. In his work, he has focused on heart failure, ischemic heart disease, and arrhythmias, among other areas.

Prior to his latest position, Soffer served as the Senior Medical Director of Clinical Development at GlaxoSmithKline. As part of his role, he was in charge of the U.S. and international clinical development for cardiology assets and pharmacovigilance activities for late-stage trials.

“I am delighted to join this dynamic team working on innovative products like istaroxime at such an exciting time of growth for the company,” said Soffer.

Connect With Your Community

Subscribe for stories that matter!

"*" indicates required fields

This field is for validation purposes and should be left unchanged.